Gilead Sciences Is Bouncing Back: Will Bullish Activity Last?
Gilead Sciences, Inc. (NASDAQ: GILD)
Gilead Sciences, along with the rest of the United States market, is working to bounce back from the brutal declines experienced on Friday. However, in the area of biotech, if there’s one company that I have faith in, it’s GILD. The reality is that Gilead Sciences is an incredibly strong company. Not only do they have a stronghold on the Hepatitis C treatment market, they are also working to come up with a cure for HIV and have an incredible drug pipeline. Ultimately, the company has proven its ability to generate earnings time and time again and I feel it will continue to do so. Therefore, if you’re looking for a solid opportunity in biotech, one of the first stocks you should look into is Gilead Sciences.
MannKind Corporation Is Gearing Up For Gains
MannKind Corporation (NASDAQ: MNKD)
MannKind Corporation, in my opinion, is an incredible company, however, there has been quite a debate around the stock. In fact, if you’re looking for the ultimate tug of war between the bulls and the bears, you’ve found it with MNKD. The debate revolves around Afrezza, MannKind’s inhaled insulin. The bears point to the fact that Afrezza hasn’t seen much by way of sales as a reason to expect declines. However, the bulls know that sales are coming. One key factor in sales in this industry is insurance coverage; and insurers are starting to take Afrezza seriously. This will lead to increased sales and upward momentum on the stock. The company is working on regulatory approval in Europe and Asia which, I believe, will start coming down the line relatively soon. So, in my opinion, MNKD is headed for strong upward momentum and presenting quite the opportunity for biotech investors.
Synergy Pharmaceuticals Is Bouncing Back
Synergy Pharmaceuticals Inc (NASDAQ: SGYP)
Synergy Pharmaceuticals is also having an incredible day in the market today. Throughout the past month, the stock has seen declines as plecanatide is taking longer than investors would like to move to an NDA. However, in my humble opinion, it’s worth being patient. Ultimately, plecanatide made it through clinical trials with flying colors. The drug, designed for the treatment of gastrointestinal conditions, has proven to not only be effective, but to be well-tolerated. As a matter of fact, those who were involved in the clinical trials experienced less of a chance of adverse side effects than those who are undergoing treatment from the current market leader. With that said, it only makes sense that the FDA will grant regulatory approval and plecanatide will enter the market sending SGYP skyrocketing!
Galena Biopharma Receives A Recommendation That Excites Investors
Galena Biopharma Inc (NASDAQ: GALE)
Finally, Galena Biopharma is having a great day in the market today. Not only is the stock bouncing back from Friday’s declines, but investors are extremely excited about a recent recommendation from the Independent Data Monitoring Committee. The recommendation was simple, GALE can reduce cardiac toxicity monitoring in it’s current Phase 3 study of NeuVax. No other suggestions were offered, insinuating that the Phase 3 study is going well. As a result, investors are pushing GALE higher in the market today and likely to continue doing so moving forward.